Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 24, 2014

Primary Completion Date

November 16, 2016

Study Completion Date

November 16, 2016

Conditions
Alagille Syndrome
Interventions
DRUG

LUM001

LUM001 administered orally

DRUG

Placebo

Placebo administered orally

Trial Locations (13)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

The Children's Hospital of Philadelphia, Philadelphia

30322

Children's Healthcare of Atlanta, Atlanta

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

77030

Baylor College of Medicine/Texas Children's Hospital, Houston

80045

Children's Hospital Colorado, Aurora

84113

University of Utah, Salt Lake City

90027

Children's Hospital Los Angeles, Los Angeles

94143

University of California at San Francisco, San Francisco

98105

Seattle Children's Hospital, Seattle

M5G 1X8

The Hospital for Sick Children, Toronto

Sponsors
All Listed Sponsors
collaborator

Childhood Liver Disease Research and Education Network

OTHER

lead

Mirum Pharmaceuticals, Inc.

INDUSTRY